Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of $23.29 million. The enterprise value is $19.51 million.

Market Cap	23.29M
Enterprise Value	19.51M

Important Dates

The last earnings date was Wednesday, May 13, 2026, after market close.

Earnings Date	May 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Aytu BioPharma has 10.73 million shares outstanding. The number of shares has increased by 16.94% in one year.

Current Share Class	10.73M
Shares Outstanding	10.73M
Shares Change (YoY)	+16.94%
Shares Change (QoQ)	+4.74%
Owned by Insiders (%)	5.63%
Owned by Institutions (%)	18.09%
Float	7.63M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.41
Forward PS	0.37
PB Ratio	0.66
P/TBV Ratio	n/a
P/FCF Ratio	14.17
P/OCF Ratio	13.88
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	0.34
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	11.87

Financial Position

The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.65.

Current Ratio	1.12
Quick Ratio	0.85
Debt / Equity	0.65
Debt / EBITDA	n/a
Debt / FCF	13.95
Interest Coverage	-3.08

Financial Efficiency

Return on equity (ROE) is -97.42% and return on invested capital (ROIC) is -36.65%.

Return on Equity (ROE)	-97.42%
Return on Assets (ROA)	-3.66%
Return on Invested Capital (ROIC)	-36.65%
Return on Capital Employed (ROCE)	-13.34%
Weighted Average Cost of Capital (WACC)	6.65%
Revenue Per Employee	$681,916
Profits Per Employee	-$410,301
Employee Count	83
Asset Turnover	0.48
Inventory Turnover	2.15

Taxes

In the past 12 months, Aytu BioPharma has paid $447,000 in taxes.

Income Tax	447,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +1.86% in the last 52 weeks. The beta is 0.25, so Aytu BioPharma's price volatility has been lower than the market average.

Beta (5Y)	0.25
52-Week Price Change	+1.86%
50-Day Moving Average	2.32
200-Day Moving Average	2.37
Relative Strength Index (RSI)	45.71
Average Volume (20 Days)	29,598

Short Selling Information

The latest short interest is 407,982, so 3.80% of the outstanding shares have been sold short.

Short Interest	407,982
Short Previous Month	457,791
Short % of Shares Out	3.80%
Short % of Float	5.35%
Short Ratio (days to cover)	7.58

Income Statement

In the last 12 months, Aytu BioPharma had revenue of $56.60 million and -$34.06 million in losses. Loss per share was -$3.71.

Revenue	56.60M
Gross Profit	36.66M
Operating Income	-6.90M
Pretax Income	-33.67M
Net Income	-34.06M
EBITDA	-2.63M
EBIT	-6.90M
Loss Per Share	-$3.71

Full Income Statement

Balance Sheet

The company has $26.72 million in cash and $22.94 million in debt, giving a net cash position of $3.78 million or $0.35 per share.

Cash & Cash Equivalents	26.72M
Total Debt	22.94M
Net Cash	3.78M
Net Cash Per Share	$0.35
Equity (Book Value)	35.14M
Book Value Per Share	3.27
Working Capital	7.35M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $1.68 million and capital expenditures -$34,000, giving a free cash flow of $1.64 million.

Operating Cash Flow	1.68M
Capital Expenditures	-34,000
Depreciation & Amortization	4.27M
Net Borrowing	383,000
Free Cash Flow	1.64M
FCF Per Share	$0.15

Full Cash Flow Statement

Margins

Gross margin is 64.78%, with operating and profit margins of -12.19% and -60.17%.

Gross Margin	64.78%
Operating Margin	-12.19%
Pretax Margin	-59.49%
Profit Margin	-60.17%
EBITDA Margin	-4.64%
EBIT Margin	-12.19%
FCF Margin	2.90%

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.94%
Shareholder Yield	-16.94%
Earnings Yield	-146.21%
FCF Yield	7.06%

Analyst Forecast

The average price target for Aytu BioPharma is $9.50, which is 333.79% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.50
Price Target Difference	333.79%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (3Y)	12.49%
EPS Growth Forecast (3Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 1:20.

Last Split Date	Jan 6, 2023
Split Type	Reverse
Split Ratio	1:20

Scores

Aytu BioPharma has an Altman Z-Score of -3.82 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3.82
Piotroski F-Score	3